Norprotonitazene is a benzimidazole derivative with a strong opioid side effect profile. It was definitively identified in early 2023. It is an analogue of etonitazene where the ethoxy group has been extended to propoxy.
While formal studies into its pharmacology haven’t been carried out, it is believed to be among the same potential as Protonitazepyne is which has been mentioned to be between 5 and 15 × activity potential of Fentanyl.
Reviews
There are no reviews yet.